A roundup of bio/pharmaceutical partnering news from Novo Nordisk/Neomorph and AbbVie/OSE Therapeutics. 

* Novo Nordisk, Neomorph in $1.46-Bn Molecular Glue Degraders Drug Deal 
* AbbVie, OSE Therapeutics In $713-M mAb Oncology Drug Pact 

---

Novo Nordisk, Neomorph in $1.46-Bn Molecular Glue Degraders Drug Deal 
Novo Nordisk and Neomorph, a San Diego, California-based bio/pharmaceutical company, have entered into a collaboration and licensing agreement to discover, develop and commercialize molecular glue degraders for treating cardiometabolic and rare diseases in a deal worth up to $1.46 billion. Neomorph is focused on advancing targeted protein degradation to destroy undruggable proteins in the development of therapeutics.  

Under the agreement, Neomorph will receive an upfront and near-term milestone payments, plus R&D funding. Neomorph is also eligible to receive future clinical, commercial, and sales milestone payments to bring the total potential deal value for multiple targets to $1.46 billion, plus tiered royalties. Neomorph will lead discovery and preclinical activities against selected targets with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization of the compounds. 

Source: Neomorph 

---

AbbVie, OSE Therapeutics In $713-M mAb Oncology Drug Pact 
AbbVie and OSE Immunotherapeutics, a Nantes, France-based clinical-stage immunotherapy company, have formed a strategic partnership to develop OSE Immunotherapeutics’ OSE-230, a monoclonal antibody for treating chronic and severe inflammation, in a deal worth up to $713 million ($48 million upfront and $665 million in milestone payments). 

Under the agreement, AbbVie will receive an exclusive global license to develop, manufacture and commercialize OSE-230, which is now in preclinical development. OSE Immunotherapeutics will receive a $48-million upfront payment and will be eligible to receive up to an additional $665 million in clinical development, regulatory, and commercial milestones. In addition, OSE Immunotherapeutics will be eligible to receive potential tiered royalties on global net sales of OSE-230. 

The transaction is subject to the satisfaction of customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. 

Source: AbbVie